Bortezomib for multiple myeloma

Bibliography

• PHEKOO KJ, SCHEY SA, RICHARDS MA et al.: A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br. J. Haematol. (2004) 127(3):299-304.
   PubMed Web of Science ®Google Scholar
• CHILD JA, MORGAN GJ, DAVIES FE et al.: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. (2003) 348(19):1875-1883.
   PubMed Web of Science ®Google Scholar
• SMITH A, WISLOFF F, SAMSON D: Guidelines on the diagnosis and management of multiple myeloma 2005. Br. J. Haematol. (2006) 132(4):410-451.
   PubMed Web of Science ®Google Scholar
• HIDESHIMA T, CHAUHAN D, RICHARDSON P, ANDERSON KC: Identification and validation of novel therapeutic targets for multiple myeloma. J. . Oncol. (2005) 23(26):6345-6350.
   Google Scholar
• CAVENAGH JD, OAKERVEE H: Thalidomide in multiple myeloma: current status and future prospects. Br. J. Haematol. (2003) 120(1):18-26.
   PubMed Web of Science ®Google Scholar
• CAVO M, ZAMAGNI E, TOSI P et al.: Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood (2005) 106(1):35-39.
   PubMed Web of Science ®Google Scholar
• PALUMBO A, BRINGHEN S, CARAVITA T et al.: Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367(9513):825-831.
   Google Scholar
• RICHARDSON PG, SCHLOSSMAN RL, WELLER E et al.: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 100(9):3063-3067.
   PubMed Web of Science ®Google Scholar
• DIMOPOULOS MA, SPENCER A, ATTAL M et al.: Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a Phase III study (MM-010). Blood (2005) 106(11):6 Abstract.
   Web of Science ®Google Scholar
• ADAMS J: The development of proteasome inhibitors as anticancer drugs. Cancer Cell (2004) 5(5):417-421.
   PubMed Web of Science ®Google Scholar
• ADAMS J, PALOMBELLA VJ, SAUSVILLE EA et al.: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. (1999) 59(11):2615-2622.
   PubMed Web of Science ®Google Scholar
• ADAMS J: Proteasome inhibition in cancer: development of PS-341. Semin. Oncol. (2001) 28(6):613-619.
   PubMed Web of Science ®Google Scholar
• MITSIADES N, MITSIADES CS, POULAKI V et al.: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA (2002) 99(22):14374-14379.
   PubMed Web of Science ®Google Scholar
• HIDESHIMA T, RICHARDSON P, CHAUHAN D et al.: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. (2001) 61(7):3071-3076.
   PubMed Web of Science ®Google Scholar
• MILLENIUM PHARMACEUTICALS I: Velcade Investigator’s Brochure (2005).
   Google Scholar
• HAMILTON AL, EDER JP, PAVLICK AC et al.: Proteasome inhibition with bortezomib (PS-341): a Phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J. Clin. Oncol. (2005) 23(25):6107-6116.
   PubMed Web of Science ®Google Scholar
• PAPANDREOU CN, DALIANI DD, NIX D et al.: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J. Clin. Oncol. (2004) 22(11):2108-2121.
   PubMed Web of Science ®Google Scholar
• JAGANNATH S, BARLOGIE B, BERENSON JR et al.: Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer (2005) 103(6):1195-1200.
   PubMed Web of Science ®Google Scholar
• CHANAN-KHAN AA, RICHARDSON P, LONIAL S et al.: Safety and efficacy of bortezomib in multiple myeloma patients with renal failure requiring dialysis. Blood (2005) 106(11):2550 Abstract.
   Web of Science ®Google Scholar
• NIX D, RYAN DP, EDER JP et al.: Pharmacokinetics of gemcitabine and the proteasome inhibitor bortezomib (formerly PS-341) in adult patients with solid malignancies. Proceedings of the Annual Meeting of the American Association of Cancer Research (2003) Abstract 5347.
   Google Scholar
• SUPKO JG, EDER JP, LYNCH RM et al.: Pharmacokinetics of irinotecan and the proteasome inhibitor bortezomib in adult patients with solid malignanicies. Proceedings of the Annual Meeting of the American Association of Clinical Oncology (2003) Abstract 544.
   Google Scholar
• PEKOL T, DANIELS JS, LABUTTI J et al.: Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab. Dispos. (2005) 33(6):771-777.
   PubMed Web of Science ®Google Scholar
• LU C, GALLEGOS R, LI P et al.: Investigation of drug-drug interaction potential of bortezomib in vivo in female sprague-dawley rats and in vitro in human liver microsomes. Drug Metab. Dispos. (2006) 34(4):702-708.
   PubMedGoogle Scholar
• ORLOWSKI RZ, STINCHCOMBE TE, MITCHELL BS et al.: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. (2002) 20(22):4420-4427.
   PubMed Web of Science ®Google Scholar
• AGHAJANIAN C, SOIGNET S, DIZON DS et al.: A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. (2002) 8(8):2505-2511.
   PubMed Web of Science ®Google Scholar
• DY GK, THOMAS JP, WILDING G et al.: A Phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin. Cancer Res. (2005) 11(9):3410-3416.
   PubMed Web of Science ®Google Scholar
• BLANEY SM, BERNSTEIN M, NEVILLE K et al.: Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children’s Oncology Group study (ADVL0015). J. Clin. Oncol. (2004) 22(23):4804-4809.
   PubMed Web of Science ®Google Scholar
• CORTES J, THOMAS D, KOLLER C et al.: Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin. Cancer Res. (2004) 10(10):3371-3376.
   PubMed Web of Science ®Google Scholar
• RICHARDSON PG, BARLOGIE B, BERENSON J et al.: A Phase II study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. (2003) 348(26):2609-2617.
   PubMed Web of Science ®Google Scholar
• BLADE J, SAMSON D, REECE D et al.: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br. J. Haematol. (1998) 102(5):1115-1123.
   PubMed Web of Science ®Google Scholar
• RICHARDSON PG, BARLOGIE B, BERENSON J et al.: Extended follow-up of a Phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial. Cancer (2006) 106(6):1316-1319.
   PubMed Web of Science ®Google Scholar
• JAGANNATH S, BARLOGIE B, BERENSON J et al.: A Phase II study of two doses of bortezomib in relapsed or refractory myeloma. Br. J. Haematol. (2004) 127(2):165-172.
   PubMed Web of Science ®Google Scholar
• BERENSON JR, JAGANNATH S, BARLOGIE B et al.: Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer (2005) 104(10):2141-2148.
   PubMed Web of Science ®Google Scholar
• MITSIADES N, MITSIADES CS, RICHARDSON PG et al.: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood (2003) 101(6):2377-2380.
   PubMed Web of Science ®Google Scholar
• MA MH, YANG HH, PARKER K et al.: The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. (2003) 9(3):1136-1144.
   PubMed Web of Science ®Google Scholar
• HAROUSSEAU JL, ATTAL M, LELEU X et al.: Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Preliminary results of an IFM Phase II Study. Haematologica (2005) 90(s1):148.
   Google Scholar
• JAGANNATH S, DURIE BG, WOLF J et al.: Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br. J. Haematol. (2005) 129(6):776-783.
   PubMed Web of Science ®Google Scholar
• KROPFF M, BISPING G, LIEBISCH P et al.: Bortezomib in combination with high-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Blood (2005) 106(11):2549 Abstract.
   Web of Science ®Google Scholar
• OAKERVEE HE, POPAT R, CURRY N et al.: PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br. J. Haematol. (2005) 129(6):755-762.
   PubMed Web of Science ®Google Scholar
• POPAT R, OAKERVEE HE, CURRY N et al.: Reduced dose PAD combination therapy (PS-341/bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma. Blood (2005) 106(11):2554 Abstract.
   Google Scholar
• BARLOGIE B, RASMUSSEN E, SHAUGHNESSY J et al.: Total therapy for newly diagnosed multiple myeloma: the Arkansas experience with 1000 patients treated with total therapy 1,2 and 3. Haematologica (2005) 90(s1):19.
   PubMed Web of Science ®Google Scholar
• MATEOS MV, BLADE J, DIAZ MEDIAVILLA J et al.: A Phase I/II national, multi-center, open-label study of velcade plus melphalan and prednisone (V-MP) in elderly untreated multiple myeloma patients. Haematologica (2005) 90(s1):149.
   Google Scholar
• POPAT R, GOFF L, OAEKERVEE HE, CAVENAGH JD, JOEL SP: Changes in Mcl-1 and Bim expression with bortezomib and melphalan therapy for multiple myeloma. Blood (2005) 106(11):2481 Abstract.
   Google Scholar
• BERENSON JR, YANG HH, SADLER K et al.: Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J. Clin. Oncol. (2006) 24(6):937-944.
   PubMed Web of Science ®Google Scholar
• POPAT R, OAKERVEE HE, FOOT N et al.: A Phase I/II study of bortezomib and low dose intravenous melphalan (BM) for relapsed multiple myeloma. Blood (2005) 106(11):2555 Abstract.
   Web of Science ®Google Scholar
• RICHARDSON P, SCHLOSSMAN R, MUNSHI N et al.: A Phase I trial of lenalidomide (REVLIMID(R)) with bortezomib (VELCADE(R)) in relapsed and refractory multiple myeloma. Blood (2005) 106(11):365 Abstract.
   Web of Science ®Google Scholar
• O’CONNOR OA: Targeting histones and proteasomes: new strategies for the treatment of lymphoma. J. Clin. Oncol. (2005) 23(26):6429-6436.
   Google Scholar
• GOY A, YOUNES A, MCLAUGHLIN P et al.: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol. (2005) 23(4):667-675.
   PubMed Web of Science ®Google Scholar
• O’CONNOR OA, WRIGHT J, MOSKOWITZ C et al.: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J. Clin. Oncol. (2005) 23(4):676-684.
   PubMed Web of Science ®Google Scholar
• STRAUSS SJ, MAHARAJ L, HOARE S et al.: Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J. Clin. Oncol. (2006) 24(13):2105-2112.
   PubMed Web of Science ®Google Scholar
• YANAMANDRA N, COLACO NM, PARQUET NA et al.: Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin. Cancer Res. (2006) 12(2):591-599.
   PubMed Web of Science ®Google Scholar
• MARKOVIC SN, GEYER SM, DAWKINS F et al.: A Phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer (2005) 103(12):2584-2589.
   PubMed Web of Science ®Google Scholar
• PRICE N, DREICER R: Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Prostate Cancer (2004) 3(3):141-143.
   PubMedGoogle Scholar
• YANG CH, GONZALEZ-ANGULO AM, REUBEN JM et al.: Bortezomib (VELCADE(R)) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann. Oncol. (2006) 17(5):813-817.
   PubMed Web of Science ®Google Scholar
• MACKAY H, HEDLEY D, MAJOR P et al.: A Phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin. Cancer Res. (2005) 11(15):5526-5533.
   PubMed Web of Science ®Google Scholar
• FANUCCHI MP, FOSSELLA F, FIDIAS P et al.: Bortezomib {+/-} docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a Phase II study. J. Clin. Oncol. (2005) 23(16 Suppl.):7034 Abstract.
   Google Scholar
• RICHARDSON PG, SONNEVELD P, SCHUSTER MW et al.: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. (2005) 352(24):2487-2498.
   PubMed Web of Science ®Google Scholar
• LONIAL S, WALLER EK, RICHARDSON PG et al.: Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood (2005) 106(12):3777-3784.
   PubMed Web of Science ®Google Scholar
• MIGUEL JFS, RICHARDSON P, SONNEVELD P et al.: Frequency, characteristics, and reversibility of peripheral neuropathy (PN) in the APEX Trial. Blood (2005) 106(11):366 Abstract.
   Google Scholar
• COLSON K, DOSS DS, SWIFT R, TARIMAN J, THOMAS TE: Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications. Clin J Oncol Nurs (2004) 8(5):473-480.
   PubMedGoogle Scholar
• MIYAKOSHI S, KAMI M, YUJI K et al.: Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood (2006) 107(9):3492-3494.
   PubMed Web of Science ®Google Scholar
• BARLOGIE B, TRICOT G, ANAISSIE E et al.: Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N. Engl. J. Med. (2006) 354(10):1021-1030.
   PubMed Web of Science ®Google Scholar
• RICHARDSON P, CHANAN-KHAN A, SCHLOSSMAN R et al.: A multicenter Phase II trial of bortezomib in patients with previously untreated multiple myeloma: efficacy with manageable toxicity in patients with unexpectedly high rates of baseline peripheral neuropathy. Blood (2005) 106(11):2548 Abstract.
   Google Scholar
• CHAUHAN D, CATLEY L, LI G et al.: A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 8(5):407-419.
   PubMed Web of Science ®Google Scholar
• MITSIADES CS, MITSIADES NS, MCMULLAN CJ et al.: Antimyeloma activity of heat shock protein-90 inhibition. Blood (2006) 107(3):1092-1100.
   PubMed Web of Science ®Google Scholar
• BAGUST A, HAYCOX AR, BOLAND A et al.: Economic evaluation of bortezomib (velcade) for relapsed and refractory multiple myeloma. Blood (2004) 104(11):268.
   Google Scholar